240 related articles for article (PubMed ID: 31185290)
1. Impact of organ-on-a-chip technology on pharmaceutical R&D costs.
Franzen N; van Harten WH; Retèl VP; Loskill P; van den Eijnden-van Raaij J; IJzerman M
Drug Discov Today; 2019 Sep; 24(9):1720-1724. PubMed ID: 31185290
[TBL] [Abstract][Full Text] [Related]
2. Organ/body-on-a-chip based on microfluidic technology for drug discovery.
Kimura H; Sakai Y; Fujii T
Drug Metab Pharmacokinet; 2018 Feb; 33(1):43-48. PubMed ID: 29175062
[TBL] [Abstract][Full Text] [Related]
3. Organ-on-a-Chip: A New Paradigm for Drug Development.
Ma C; Peng Y; Li H; Chen W
Trends Pharmacol Sci; 2021 Feb; 42(2):119-133. PubMed ID: 33341248
[TBL] [Abstract][Full Text] [Related]
4. Recent lab-on-chip developments for novel drug discovery.
Khalid N; Kobayashi I; Nakajima M
Wiley Interdiscip Rev Syst Biol Med; 2017 Jul; 9(4):. PubMed ID: 28211993
[TBL] [Abstract][Full Text] [Related]
5. Emerging technologies for prediction of drug candidate efficacy in the preclinical pipeline.
Menshykau D
Drug Discov Today; 2017 Nov; 22(11):1598-1603. PubMed ID: 28545837
[TBL] [Abstract][Full Text] [Related]
6. How to improve R&D productivity: the pharmaceutical industry's grand challenge.
Paul SM; Mytelka DS; Dunwiddie CT; Persinger CC; Munos BH; Lindborg SR; Schacht AL
Nat Rev Drug Discov; 2010 Mar; 9(3):203-14. PubMed ID: 20168317
[TBL] [Abstract][Full Text] [Related]
7. A Review of the Application of Body-on-a-Chip for Drug Test and Its Latest Trend of Incorporating Barrier Tissue.
Jin H; Yu Y
J Lab Autom; 2016 Oct; 21(5):615-24. PubMed ID: 26721822
[TBL] [Abstract][Full Text] [Related]
8. The productivity crisis in pharmaceutical R&D.
Pammolli F; Magazzini L; Riccaboni M
Nat Rev Drug Discov; 2011 Jun; 10(6):428-38. PubMed ID: 21629293
[TBL] [Abstract][Full Text] [Related]
9. Challenges faced by the pharmaceutical industry: training graduates for employment in pharmaceutical R&D.
Mooney KG
Eur J Pharm Sci; 2001 Feb; 12(4):353-9. PubMed ID: 11231101
[TBL] [Abstract][Full Text] [Related]
10. Imaging microphysiological systems: a review.
Peel S; Jackman M
Am J Physiol Cell Physiol; 2021 May; 320(5):C669-C680. PubMed ID: 33356942
[TBL] [Abstract][Full Text] [Related]
11. Does R&D pay?
Cavalla D; Minhas R
Drug Discov Today; 2010 Mar; 15(5-6):230-4. PubMed ID: 19931643
[TBL] [Abstract][Full Text] [Related]
12. Systematic risk identification and assessment using a new risk map in pharmaceutical R&D.
Schuhmacher A; Brieke C; Gassmann O; Hinder M; Hartl D
Drug Discov Today; 2021 Dec; 26(12):2786-2793. PubMed ID: 34229082
[TBL] [Abstract][Full Text] [Related]
13. A flexible blueprint for the future of drug development.
Barker R
Lancet; 2010 Jan; 375(9712):357-9. PubMed ID: 20113813
[No Abstract] [Full Text] [Related]
14. Organ-on-a-chip devices advance to market.
Zhang B; Radisic M
Lab Chip; 2017 Jul; 17(14):2395-2420. PubMed ID: 28617487
[TBL] [Abstract][Full Text] [Related]
15. Decline in economic returns from new drugs raises questions about sustaining innovations.
Berndt ER; Nass D; Kleinrock M; Aitken M
Health Aff (Millwood); 2015 Feb; 34(2):245-52. PubMed ID: 25646104
[TBL] [Abstract][Full Text] [Related]
16. Changing R&D models in research-based pharmaceutical companies.
Schuhmacher A; Gassmann O; Hinder M
J Transl Med; 2016 Apr; 14(1):105. PubMed ID: 27118048
[TBL] [Abstract][Full Text] [Related]
17. Medications development for substance-use disorders: contextual influences (dis)incentivizing pharmaceutical-industry positioning.
Janero DR
Expert Opin Drug Discov; 2014 Nov; 9(11):1265-79. PubMed ID: 25162124
[TBL] [Abstract][Full Text] [Related]
18. Navigating tissue chips from development to dissemination: A pharmaceutical industry perspective.
Ewart L; Fabre K; Chakilam A; Dragan Y; Duignan DB; Eswaraka J; Gan J; Guzzie-Peck P; Otieno M; Jeong CG; Keller DA; de Morais SM; Phillips JA; Proctor W; Sura R; Van Vleet T; Watson D; Will Y; Tagle D; Berridge B
Exp Biol Med (Maywood); 2017 Oct; 242(16):1579-1585. PubMed ID: 28622731
[TBL] [Abstract][Full Text] [Related]
19. Should financial incentives be used to differentially reward 'me-too' and innovative drugs?
Pekarsky B
Pharmacoeconomics; 2010; 28(1):1-17. PubMed ID: 20014872
[TBL] [Abstract][Full Text] [Related]
20. In search of sustainability: process R&D in light of current pharmaceutical industry challenges.
Federsel HJ
Drug Discov Today; 2006 Nov; 11(21-22):966-74. PubMed ID: 17055405
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
